CTLA4 and melanoma: Long-term follow-up efficacy data from phase II and III trials and especially the toxicity burden of the anti-CTLA4 and anti-PD1 combination have raised questions on what could be the best frontline treatment for advanced melanoma and which are the best candidates for combination or single-agent therapy.